Medicenna Reports Second Quarter Fiscal 2021 Financial Results and Operational Highlights

NEXT STORY
BioCryst Presents Data Showing Sustained Attack Rate Reductions, Improved Patient Satisfaction and Quality of Life for HAE Patients Taking Berotralstat in APeX-2 Trial
PREV STORY
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Zai Lab Announces Proposed Public Offering of American Depositary Shares

author_avatar
NASDAQ Market News

North America personal protective equipment for infection control market to surpass USD 7 billion by 2026

author_avatar
NASDAQ Market News

OncoC4, Inc. Reports Phase Ia Data on Safety and Clinical Activities of ONC-392 (Nextgen Anti-CTLA-4) Monotherapy for Stage IV Solid Tumors

author_avatar
NASDAQ Market News